GlassScriptPhysician profile
Sateesh Reddy Prakash
NPI 1205021482
$2,808.69
in general payments reported to CMS, 2019-2025
26 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $247 · 2021: $537 · 2022: $338 · 2023: $418 · 2024: $421 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Education: $18.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.78 |
| Education | $18.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.04 | 2019-2025 | |
| Braintree Laboratories, INC. | $379.91 | 2019-2025 | Sutab, Suflave |
| Medtronic, INC. | $163.46 | 2024-2025 | Interstim |
| Janssen Biotech, INC. | $117.65 | 2019-2024 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $117.20 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $115.16 | 2021-2025 | Eohilia, Entyvio |
| Intercept Pharmaceuticals, INC. | $111.15 | 2019-2024 | |
| Redhill Biopharma INC. | $105.38 | 2020-2021 | |
| Boston Scientific Corporation | $101.10 | 2020 | |
| Merck Sharp & Dohme LLC | $98.24 | 2022-2024 | Dificid |
| Mauna Kea Technologies, INC. | $95.29 | 2023-2025 | |
| Glaxosmithkline, LLC. | $95.13 | 2023 | Nucala |
| Qol Medical, LLC | $82.11 | 2019-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.32 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $63.96 | 2019-2023 | Linzess |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $53.96 | 2020-2025 | |
| Daiichi Sankyo INC. | $53.76 | 2019-2021 | |
| Celgene Corporation | $39.38 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $25.44 | 2025 | Rezdiffra |
| Lilly USA, LLC | $25.04 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $22.00 | 2024 | |
| Celltrion USA INC. | $18.23 | 2024 | Zymfentra |
| Novo Nordisk INC | $18.18 | 2025 | Wegovy |
| Micro-Tech Endoscopy USA, INC. | $15.41 | 2022 | |
| Olympus America INC. | $15.23 | 2020 | |
| Covidien LP | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sateesh Prakash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.